

## CALENDAR OF REPORTING DATES FOR TENNESSEE SPECIAL ELECTIONS—Continued

Report	Close of books <sup>1</sup>	Reg./cert. & overnight mailing deadline	Filing deadline
Year-End .....	12/31/2025	01/31/2026	<sup>2</sup> 01/31/2026

<sup>1</sup> The reporting period always begins the day after the closing date of the last report filed. If the committee is new and has not previously filed a report, the first report must cover all activity that occurred before the committee registered as a political committee up through the close of books for the first report due.

<sup>2</sup> Notice that this filing deadline falls on a weekend or federal holiday. Filing deadlines are not extended when they fall on nonworking days. Accordingly, reports filed on paper by methods other than registered, certified or overnight mail must be received before the Commission's close of business on the last business day before the deadline.

Dated: July 30, 2025.

On behalf of the Commission,

**Shana M. Broussard,**

*Chair, Federal Election Commission.*

[FR Doc. 2025-14730 Filed 8-1-25; 8:45 am]

**BILLING CODE 6715-01-P**

## FEDERAL RESERVE SYSTEM

### Change in Bank Control Notices; Acquisitions of Shares of a Bank or Bank Holding Company

The notificants listed below have applied under the Change in Bank Control Act (Act) (12 U.S.C. 1817(j)) and § 225.41 of the Board's Regulation Y (12 CFR 225.41) to acquire shares of a bank or bank holding company. The factors that are considered in acting on the applications are set forth in paragraph 7 of the Act (12 U.S.C. 1817(j)(7)).

The public portions of the applications listed below, as well as other related filings required by the Board, if any, are available for immediate inspection at the Federal Reserve Bank(s) indicated below and at the offices of the Board of Governors. This information may also be obtained on an expedited basis, upon request, by contacting the appropriate Federal Reserve Bank and from the Board's Freedom of Information Office at <https://www.federalreserve.gov/foia/request.htm>. Interested persons may express their views in writing on the standards enumerated in paragraph 7 of the Act.

Comments received are subject to public disclosure. In general, comments received will be made available without change and will not be modified to

remove personal or business information including confidential, contact, or other identifying information. Comments should not include any information such as confidential information that would not be appropriate for public disclosure.

Comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors, Ann E. Misback, Secretary of the Board, 20th Street and Constitution Avenue NW, Washington, DC 20551-0001, not later than August 19, 2025.

*A. Federal Reserve Bank of St. Louis (Holly A. Rieser, Senior Manager) P.O. Box 442, St. Louis, Missouri 63166-2034. Comments can also be sent electronically to*

*Comments.applications@stls.frb.org:*  
**1. The Sharon K. Garrett Marital Trust, created under the Sharon K. Garrett Revocable Trust dated November 1, 2000, as amended, Purdy, Missouri; John H. Garrett, Southport, North Carolina, and Jeffrey S. Scott, Purdy, Missouri, as co-trustees; and the Garrett Family Bank Trust, created under the Irrevocable Trust Agreement dated March 20, 2024, Purdy, Missouri; John H. Garrett and Filip J. Garrett, Brookside, Missouri, as co-trustees; as a group acting in concert, to retain voting shares of Purdy Bancshares, Inc., Monett, Missouri, and thereby indirectly retain voting shares of First State Bank of Purdy, Purdy, Missouri.**

Board of Governors of the Federal Reserve System.

**Erin Cayce,**

*Assistant Secretary of the Board.*

[FR Doc. 2025-14726 Filed 8-1-25; 8:45 am]

**BILLING CODE P**

## EARLY TERMINATIONS GRANTED

[June 1, 2025, through June 30, 2025]

## FEDERAL TRADE COMMISSION

### Granting of Requests for Early Termination of the Waiting Period Under the Premerger Notification Rules

Section 7A of the Clayton Act, 15 U.S.C. 18a, as added by Title II of the Hart-Scott-Rodino Antitrust Improvements Act of 1976, requires persons contemplating certain mergers or acquisitions to give the Federal Trade Commission and the Assistant Attorney General advance notice and to wait designated periods before consummation of such plans. Section 7A(b)(2) of the Act permits the agencies, in individual cases, to terminate this waiting period prior to its expiration and requires that notice of this action be published in the **Federal Register**.

The following transactions were granted early termination—on the dates indicated—of the waiting period provided by law and the premerger notification rules. The listing for each transaction includes the transaction number and the parties to the transaction. The grants were made by the Federal Trade Commission and the Assistant Attorney General for the Antitrust Division of the Department of Justice. Neither agency intends to take any action with respect to these proposed acquisitions during the applicable waiting period.

06/05/2025

20251188 .....	G	BayPine Commander Co-Invest, LP; Webster Capital IV, L.P.; BayPine Commander Co-Invest, LP.
20251195 .....	G	Novant Health, Inc.; American Healthcare Systems Corp., Inc.; Novant Health, Inc.
20251214 .....	G	Silver Lake Partners VII, L.P.; Intel Corporation; Silver Lake Partners VII, L.P.
20251245 .....	G	Cove Hill Partners Fund II, L.P.; Swiftly Parent, Inc.; Cove Hill Partners Fund II, L.P.
20251246 .....	G	Sofidel S.p.A.; Royal Interco, LLC; Sofidel S.p.A.

## EARLY TERMINATIONS GRANTED—Continued

[June 1, 2025, through June 30, 2025]

20251254 .....	G	Fideicomiso F/125; Macquarie Infrastructure Partners IV, L.P.; Fideicomiso F/125.
20251256 .....	G	Ultra Ultimate Parent, LP; GTCR Fund XII/B LP; Ultra Ultimate Parent, LP.
20251263 .....	G	Altas Partners Holdings III LP; Redwood Services Holdco, LLC; Altas Partners Holdings III LP.
20251274 .....	G	Mayville Engineering Company, Inc.; Tide Rock YieldCo, LLC; Mayville Engineering Company, Inc.

## 06/06/2025

20251202 .....	G	WestView Capital Partners V, L.P.; Thierry and Elizabeth Beckers; WestView Capital Partners V, L.P.
20251236 .....	G	General Atlantic Partners 100, L.P.; EQH Parent, LLC; General Atlantic Partners 100, L.P.
20251244 .....	G	Church & Dwight Co., Inc.; Andrea Lisbona; Church & Dwight Co., Inc.
20251265 .....	G	Dream Games Dijital Teknolojiler Anonim Sirketi; Dream Games Holdings Ltd; Dream Games Dijital Teknolojiler Anonim Sirketi.

## 06/12/2025

20251225 .....	G	ISQ Global Infrastructure Fund III, L.P.; Mobico Group PLC; ISQ Global Infrastructure Fund III, L.P.
20251231 .....	G	Ares Acquisition Corporation II; Kodiak Robotics, Inc.; Ares Acquisition Corporation II.
20251248 .....	G	KKR North America Fund XIV SCSp; S&P Global Inc.; KKR North America Fund XIV SCSp.
20251249 .....	G	KKR North America Fund XIV SCSp; CME Group Inc.; KKR North America Fund XIV SCSp.
20251251 .....	G	Impactive Capital Fund LP; Advanced Drainage Systems, Inc.; Impactive Capital Fund LP.
20251262 .....	G	General Atlantic Partners 100, L.P.; Blackstone Capital Partners VII L.P.; General Atlantic Partners 100, L.P.
20251279 .....	G	AMETEK, Inc.; FARO Technologies, Inc.; AMETEK, Inc.

## 06/16/2025

20251237 .....	G	The Resolute Fund VI, L.P.; PP III Continuation Fund, L.P.; The Resolute Fund VI, L.P.
20251247 .....	G	BNP Paribas S.A.; AXA S.A.; BNP Paribas S.A.
20251269 .....	G	Marriott International, Inc.; citizenM Holding B.V.; Marriott International, Inc.
20251277 .....	G	HP TLE Holdings, LP; Golden Gate Capital Opportunity Fund, L.P.; HP TLE Holdings, LP.
20251295 .....	G	SunCoke Energy, Inc.; Flame Aggregator, LLC; SunCoke Energy, Inc.
20251297 .....	G	GreyLion Fund III LP; Thomas R. Testwuide, Jr. 1992 Trust; GreyLion Fund III LP.
20251301 .....	G	BNT Partners Trust; BAM Partners Trust; BNT Partners Trust.
20251303 .....	G	TSG9 L.P.; EOS Fitness Holdings LLC; TSG9 L.P.
20251304 .....	G	Saguaro Coinvestor Holdings L.P.; EOS Fitness Holdings, LLC; Saguaro Coinvestor Holdings L.P.
20251310 .....	G	BioMarin Pharmaceutical Inc.; Inozyme Pharma, Inc.; BioMarin Pharmaceutical Inc.

## 06/23/2025

20250614 .....	G	Omnicom Group Inc.; The Interpublic Group of Companies, Inc.; Omnicom Group Inc.
----------------	---	--

## 06/24/2025

20251284 .....	G	3G Fund VI, L.P.; Robert Greenberg; 3G Fund VI, L.P.
20251314 .....	G	General Atlantic Partners 100, L.P.; Gravie, Inc.; General Atlantic Partners 100, L.P.
20251315 .....	G	Regeneron Pharmaceuticals, Inc.; Abeona Therapeutics Inc.; Regeneron Pharmaceuticals, Inc.
20251329 .....	G	HomeStreet, Inc.; Ford Ultimate Management II, LLC; HomeStreet, Inc.
20251330 .....	G	AstraZeneca PLC; Pathos AI, Inc.; AstraZeneca PLC.
20251339 .....	G	IW Topco LLC; KPS Special Situations Mid-Cap Fund, LP; IW Topco LLC.

## 06/25/2025

20250709 .....	S	Mars, Incorporated; Kellanova; Mars, Incorporated.
20251276 .....	G	Atlantic Park Strategic Capital Fund II (Offshore), L.P.; Claranova S.E.; Atlantic Park Strategic Capital Fund II (Offshore), L.P.
20251294 .....	G	Trident IX, L.P.; Northlane Capital Partners II LP; Trident IX, L.P.
20251299 .....	G	United Parcel Service, Inc.; Michael Andlauer; United Parcel Service, Inc.
20251320 .....	G	Novo Nordisk Foundation; Septerna, Inc.; Novo Nordisk Foundation.

## 06/27/2025

20250617 .....	S	Quest Diagnostics Incorporated; Corewell Health; Quest Diagnostics Incorporated.
20251305 .....	G	KKR Asian Fund IV Japan AIV 2 L.P.; Topcon Corporation; KKR Asian Fund IV Japan AIV 2 L.P.
20251306 .....	G	Savage Companies Inc.; James Vanasek; Savage Companies Inc.
20251307 .....	G	Savage Companies Inc.; P. Donnell Noone; Savage Companies Inc.
20251308 .....	G	TPG Partners IX, L.P.; Sabre Corporation; TPG Partners IX, L.P.
20251328 .....	G	WCAS XIV, L.P.; ACD Parent, LLC; WCAS XIV, L.P.
20251359 .....	G	Rosebank Industries PLC; Cerberus Institutional Partners VI, L.P.; Rosebank Industries PLC.

**FOR FURTHER INFORMATION CONTACT:**  
Theresa Kingsberry (phone: 202–326–  
3100), Program Support Specialist,

Federal Trade Commission Premerger  
Notification Office, Bureau of

Competition, Room CC–5301,  
Washington, DC 20024.

By direction of the Commission.

**Joel Christie,**

*Acting Secretary.*

[FR Doc. 2025–14723 Filed 8–1–25; 8:45 am]

**BILLING CODE 6750–01–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. FDA–2025–N–2422]

#### Teva Branded Pharmaceutical Products R&D, Inc., et al.; Withdrawal of Approval of 39 New Drug Applications

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA or Agency) is withdrawing approval of 39 new drug applications (NDAs) from multiple applicants. The applicants notified the Agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.

**DATES:** Approval is withdrawn as of September 3, 2025.

**FOR FURTHER INFORMATION CONTACT:** Kimberly Lehrfeld, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, Rm. 6226, Silver Spring, MD 20993–0002, 301–

796–3137, *Kimberly.Lehrfeld@fda.hhs.gov*.

**SUPPLEMENTARY INFORMATION:** The applicants listed in table 1 have informed FDA that these drug products are no longer marketed and have requested that FDA withdraw approval of the applications under the process in § 314.150(c) (21 CFR 314.150(c)). The applicants have also, by their requests, waived their opportunity for a hearing. Withdrawal of approval of an application or abbreviated application under § 314.150(c) is without prejudice to refiling.

TABLE1—NDAS FOR WHICH APPROVAL IS WITHDRAWN

Application No.	Drug	Applicant
NDA 012674 .....	Hexadrol (dexamethasone), Elixir, 0.5 mg/5 milliliter (mL) .....	Aspen Global Inc., c/o Lachman Consultant Services, Inc., 1600 Stewart Ave., Westbury, NY 11590.
NDA 012675 .....	Hexadrol (dexamethasone) Tablets, 0.5 mg, 0.75 mg, 1.5 mg, and 4 mg.	Do.
NDA 014694 .....	Hexadrol (dexamethasone sodium phosphate) Injectable, Equivalent to (EQ) 4 mg phosphate/mL, EQ 10 mg phosphate/mL, and EQ 20 mg phosphate/mL.	Do.
NDA 016012 .....	Vivactil (protriptyline hydrochloride (HCl)) Tablets, 5 mg and 10 mg ...	Teva Women's Health, Inc, 145 Brandywine Parkway, West Chester, PA 19380.
NDA 016792 .....	Surmontil (trimipramine maleate) Capsules, EQ 25 mg base, EQ 50 mg base, and EQ 100 mg base.	Do.
NDA 016798 .....	Sinequan (doxepin HCl) Capsules, EQ 10 mg base, EQ 25 mg base, EQ 50 mg base, EQ 75 mg base, EQ 100 mg base, and EQ 150 mg base.	Pfizer Inc, 66 Hudson Blvd. East, New York, NY 10001.
NDA 017516 .....	Sinequan (doxepin HCl) Concentrate, EQ 10 mg base/mL .....	Do.
NDA 017525 .....	Loxitane (loxapine succinate) Capsules, EQ 5 mg base, EQ 10 mg base, EQ 25 mg base, and EQ 50 mg base; Loxitane (loxapine succinate) Tablets, EQ 10 mg base, EQ 25 mg base, and EQ 50 mg base.	Teva Branded Pharmaceutical Products R&D, LLC, 145 Brandywine Parkway, West Chester, PA 19380.
NDA 017658 .....	Loxitane C (loxapine HCl) Concentrate, EQ 25 mg base/mL .....	Do.
NDA 017693 .....	Drytec Technetium Tc99m Generator (technetium Tc99m sodium pertechnetate generator) Solution, 830–16600 millicurie (mCi)/generator, and 68–2703 mCi/generator.	GE HealthCare, 251 Locke Dr., Marlborough, MA 01752.
NDA 018110 .....	Thallous Chloride TI-201 (thallous chloride TI-201) Injectable, 1 mCi/mL.	Do.
NDA 018920 .....	M.V.I. Pediatric (ascorbic acid 80mg/vial; biotin 0.02 mg/vial; cyanocobalamin 0.001mg/vial; dexpantenol 5 mg/vial; ergocalciferol 0.01mg/vial; folic acid 0.14 mg/vial; niacinamide 17 mg/vial; phytonadione 0.2 mg/vial; pyridoxine HCl 1 mg/vial; riboflavin 5'-phosphate sodium 1.4 mg/vial; thiamine HCl EQ 1.2 mg base/vial; vitamin A 0.7 mg/vial; vitamin E 7 mg/vial) For Solution.	Hospira, Inc., a Pfizer company, 275 North Field Drive, Lake Forest, IL 60045.
NDA 019240 .....	E–Z Scrub 201 (povidone-iodine) Sponge, 20% .....	Becton, Dickinson and Company, 75 N Fairway Dr., Vernon Hills, IL 60061.
NDA 019476 .....	E–Z Scrub 241 (povidone-iodine) Sponge, 10% .....	Do.
NDA 020551 .....	Nimbex (cisatracurium besylate) Injectable, EQ 2 mg base/mL; Nimbex Preservative Free (cisatracurium besylate) Injectable, EQ 2 mg base/mL and EQ 10 mg base/mL.	AbbVie Inc., N Waukegan Rd., North Chicago, IL 60064.
NDA 020655 .....	Alora (estradiol) Extended-release Films, 0.025 mg/24 hour, 0.05 mg/24 hour, 0.075 mg/24 hour, and 0.1 mg/24 hour.	Do.
NDA 020933 .....	Viramune (nevirapine), Suspension, 50 mg/5 mL .....	Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Rd., Ridgefield, CT 06877–0369.
NDA 021071 .....	Avandia (rosiglitazone maleate) Tablets, EQ 2 mg base, EQ 4 mg base, and EQ 8 mg base.	Woodward Pharma Services, LLC, 11705 Boyette Rd., Riverview, FL 33569.
NDA 021290 .....	Zinecard (dexrazoxane HCl) Injectable, EQ 250 mg base/vial and EQ 500 mg base/vial.	Pfizer Inc.
NDA 021591 .....	Riomet (metformin HCl) Solution, 500 mg/5 mL .....	Ranbaxy Signature LLC c/o Sun Pharmaceutical Industries, Inc., 2 Independence Way, Princeton, NJ 08540.